Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Finished Goods (2016 - 2019)

Plus Therapeutics (PSTV) has disclosed Finished Goods for 9 consecutive years, with $1.7 million as the latest value for Q1 2019.

  • On a quarterly basis, Finished Goods fell 13.33% to $1.7 million in Q1 2019 year-over-year; TTM through Mar 2019 was $1.7 million, a 13.33% decrease, with the full-year FY2018 number at $1.6 million, down 8.2% from a year prior.
  • Finished Goods was $1.7 million for Q1 2019 at Plus Therapeutics, up from $1.6 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $2.5 million in Q4 2015 to a low of $1.5 million in Q1 2015.
  • A 5-year average of $1.9 million and a median of $1.8 million in 2017 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: crashed 33.92% in 2015, then skyrocketed 50.79% in 2016.
  • Plus Therapeutics' Finished Goods stood at $2.5 million in 2015, then dropped by 26.45% to $1.8 million in 2016, then dropped by 2.14% to $1.8 million in 2017, then decreased by 8.2% to $1.6 million in 2018, then grew by 2.69% to $1.7 million in 2019.
  • Per Business Quant, the three most recent readings for PSTV's Finished Goods are $1.7 million (Q1 2019), $1.6 million (Q4 2018), and $1.7 million (Q3 2018).